Cargando…
Transient cytotoxicity of (131)I beta radiation in hyperthyroid patients treated with radioactive iodine
BACKGROUND & OBJECTIVES: Radioiodine ((131)I) or radioactive iodine in low doses is used worldwide as the first line of management in the treatment of hyperthyroidism. Information is available on the extent and severity of cell damage after a high dose radioiodine ((131)I) therapy for thyroid ca...
Autores principales: | Sundaram, P. Shanmuga, Padma, S., Sudha, S., Sasikala, K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103173/ https://www.ncbi.nlm.nih.gov/pubmed/21537093 |
Ejemplares similares
-
Outcomes of Radioactive Iodine ((131)I) Therapy among Hyperthyroid patients
por: Khan, Muhammad Sajjad Ali, et al.
Publicado: (2023) -
Treating Hyperthyroidism with Radioactive Iodine
por: Harding, L K
Publicado: (1993) -
Estimation of effective half life of clearance of radioactive Iodine ((131)I) in patients treated for hyperthyroidism and carcinoma thyroid
por: Ravichandran, R, et al.
Publicado: (2010) -
Efficacy of radioactive iodine treatment of graves’ hyperthyroidism using a single calculated (131)I dose
por: Wong, Ka Kit, et al.
Publicado: (2018) -
Impact of lithium on radioactive iodine therapy for hyperthyroidism
por: Lingudu, Brahmanandam, et al.
Publicado: (2014)